Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIMID
2022-502968-20-01Phase 2Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgotinib in Behçet's disease (BD), Autoimmune Myopathies and IgG4-related disease (IgG4-RD), sponsored by University Medical Center Utrecht. Primary endpoint: EuroQol 5D-5L (EQ-5D-5L) form. Planned start Jun 2023; status: withdrawn.
02
Drugs
filgotinib
03
Conditions
Behçet's disease (BD)Autoimmune MyopathiesIgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2022-502968-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502968-20-01.